11/27/2020 1:07:55 PM
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/20/2020 4:20:29 PM
Xeris Pharmaceuticals Appoints John Shannon President And COO
8/10/2020 7:20:05 AM
Xeris Pharma Q2 Net Loss Of $24.1 Mln Or $0.63/Shr Vs Loss Of $34.4
mln Or $1.28/Shr Last Year
6/25/2020 9:39:33 PM
Xeris Announces Pricing Of Public Offerings Of $20 Mln Of
Common Stock And $75 Mln Of 5.00% Senior Notes Due 2025
6/24/2020 4:05:08 PM
Xeris Announces Proposed Public Offerings Of $20 Mln Of
Common Stock And $60 Mln Of Convertible Senior Notes
6/18/2020 8:07:28 AM
Xeris Pharma Announces Positive Topline Results From Phase 2
Comparative Study Of XP-3924
5/14/2020 3:10:19 AM
Xeris Pharma Inks Deal With Clinigen To Supply And Distribute Gvoke Outside The U.S
4/20/2020 8:04:23 AM
Xeris Pharmaceuticals Announces Positive Topline Results From Phase 1b Study Of Diazepam Injection
3/11/2020 6:05:35 AM
Xeris Pharma Q4 Net Loss Of $33.1 Mln Or $1.23/Shr Vs Loss Of $20.4 Mln Or $0.98/Shr Last Year
2/11/2020 7:31:41 PM
Xeris Pharma Prices Underwritten Public Offering Of 9 Mln Shares At $4.15/shr
9/19/2019 8:09:16 AM
Xeris Pharma Begins Dosing Patients In Phase 2 Clinical Trial Of Novel Fixed-Ratio Co-Formulation Of Pramlintide-Insulin